TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15016635

Group type: EXPERIMENTAL
Intervention: Exercise-induced preconditioning (FWOP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (SWOP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pharmacologically induced preconditioning (PI-SWOP) with 10 mg nitroglycerin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 20
Study: 11214746

Group type: EXPERIMENTAL
Intervention: PC-coated stents
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncoated stents
Number of subjects: 30
Study: 8708426

Group type: EXPERIMENTAL
Intervention: Ankle pressure recommendation amendment from < or = 50 mmHg to >50 mmHg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Big toe pressure recommendation amendment from < or = 30 mmHg to >30 mmHg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Inclusion of Doppler index and tcPO2 as additional parameters
Number of subjects: 140
Study: 2650695

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplement (10 g of fish oil containing 3 g n-3 fatty acids, 1.8 g eicosapentaenoic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (isoenergetic supplement containing olive oil)
Number of subjects: 0
Study: 334110

Group type: EXPERIMENTAL
Intervention: Cephalothin sodium (1 gm IV at the beginning of operation and 1 gm one hour later)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cephalothin sodium (2 gm IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31567810

Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients requesting appointments via telephone
Number of subjects: 71

Group type: COMPARATOR
Intervention: English-speaking patients requesting appointments via telephone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients instructed to bring a friend or family member for translation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients told that the provider spoke sufficient Spanish
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients told that an interpreter would be available
Number of subjects: 71

Group type: COMPARATOR
Intervention: Comparison of access to appointments between Spanish-speaking and English-speaking patients
Number of subjects: 71
Study: 29384903

Group type: EXPERIMENTAL
Intervention: tedizolid phosphate 200 mg once daily for 6 days
Number of subjects: 813

Group type: COMPARATOR
Intervention: linezolid 600 mg twice daily for 10 days
Number of subjects: 813
Study: 25449222

Group type: EXPERIMENTAL
Intervention: Infant Health and Development Program (intervention)
Number of subjects: 875
Study: 24210590

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs) losartan
Number of subjects: 3238

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs) irbesartan
Number of subjects: 3238

Group type: COMPARATOR
Intervention: Confirmed eGFR decline of 57%, 40%, 30%, or 20%
Number of subjects: 3238

Group type: COMPARATOR
Intervention: Confirmed doubling of serum creatinine level
Number of subjects: 3238
Study: 21496112

Group type: EXPERIMENTAL
Intervention: Eccentric training for wrist extensors with a forearm band, 6-week home exercise regimen.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group receiving a forearm band only.
Number of subjects: 42
Study: 20629516

Group type: EXPERIMENTAL
Intervention: Harmonic shear as a single working instrument, two-trocar technique (group 1 = 80 patients)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Regular clip/cautery, three-trocar technique (group 2 = 80 patients)
Number of subjects: 160
Study: 17694461

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (100 microg/min for 12 hours after PCI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 200
Study: 15662235

Group type: EXPERIMENTAL
Intervention: Continue antihypertensive therapy
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Stop antihypertensive therapy
Number of subjects: 2900
Study: 11985763

Group type: EXPERIMENTAL
Intervention: Salbutamol, 0.8 mg four times daily for 2 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control situation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15
Study: 9496408

Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine 3.0 g (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard agents (nitrofurantoin, norfloxacin, trimethoprim/sulfamethoxazole)
Number of subjects: 0
Study: 8701877

Group type: EXPERIMENTAL
Intervention: Exercise training on a cycle ergometer 3 times a week for 8 weeks at 60% of peak oxygen uptake (Group T)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 43
Study: 1876465

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TMP-SMX and prednisone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 6299050

Group type: EXPERIMENTAL
Intervention: Cyclofenil, 400 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conjugated estrogens, 1.25 mg/day
Number of subjects: 10
Study: 30852538

Group type: EXPERIMENTAL
Intervention: Stay Safe Link
Number of subjects: 434

Group type: COMPARATOR
Intervention: Stay Safe
Number of subjects: 434
Study: 28112473

Group type: EXPERIMENTAL
Intervention: EXCEL2 stent
Number of subjects: 833
Study: 27959333

Group type: EXPERIMENTAL
Intervention: Single high dose of dexamethasone
Number of subjects: 0
Study: 24812304

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 1663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1663
Study: 22657254

Group type: EXPERIMENTAL
Intervention: Bevacizumab + FOLFIRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 0
Study: 19948811

Group type: EXPERIMENTAL
Intervention: Nurse-led cardiovascular risk management including risk assessment, risk communication, a decision aid and adapted motivational interviewing
Number of subjects: 615

Group type: COMPARATOR
Intervention: Minimal nurse-led intervention (Control)
Number of subjects: 615
Study: 17589976

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 MAC end‐tidal concentration)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Propofol (2 to 3 mg kg(‐1) hour(‐1))
Number of subjects: 32
Study: 15502598

Group type: EXPERIMENTAL
Intervention: Paroxetine (10‐50 mg/day)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 207
Study: 11434074

Group type: EXPERIMENTAL
Intervention: Mailed educational pamphlet ('Early Prostate Cancer')
Number of subjects: 342

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 342
Study: 9753251

Group type: EXPERIMENTAL
Intervention: Rebamipide (300 mg three times a day) with omeprazole (40 mg twice a day) and amoxicillin (1500 mg three times a day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no rebamipide) with omeprazole (40 mg twice a day) and amoxicillin (1500 mg three times a day)
Number of subjects: 120
Study: 8665047

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2680275

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce calorie intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and calorie intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and increase potassium intake
Number of subjects: 841

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 841
Study: 987578

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29474685

Group type: EXPERIMENTAL
Intervention: HealtheSteps™ lifestyle prescription program (in-person coaching sessions, goal setting and tracking, technology supports)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HealtheSteps™ lifestyle prescription program
Number of subjects: 25
Study: 28605781

Group type: EXPERIMENTAL
Intervention: CNI-free arm (everolimus with mycophenolic acid)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: low-CNI group (everolimus with reduced CNI)
Number of subjects: 499

Group type: COMPARATOR
Intervention: standard CNI group (cyclosporine with mycophenolic acid)
Number of subjects: 499
Study: 26342289

Group type: EXPERIMENTAL
Intervention: Intranasal AZD8848 20 µg three times weekly
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intranasal AZD8848 60 µg once weekly
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 23455335

Group type: EXPERIMENTAL
Intervention: Goat milk formula
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cow milk-based formula
Number of subjects: 90

Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 90
Study: 21205592

Group type: EXPERIMENTAL
Intervention: PCI with drug eluting stents
Number of subjects: 80

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 80
Study: 18285440

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized treatments
Number of subjects: 0
Study: 16438980

Group type: EXPERIMENTAL
Intervention: Question repetition (questions asked three times)
Number of subjects: 136
Study: 12589445

Group type: EXPERIMENTAL
Intervention: Prior word length cuing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target word frequency (high or low)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exterior letters consistency (large or small pool of candidate words)
Number of subjects: 0
Study: 10699160

Group type: EXPERIMENTAL
Intervention: Daclizumab (1.0 mg per kilogram of body weight), given intravenously within 24 hours after surgery and every two weeks thereafter for a total of five doses
Number of subjects: 55

Group type: COMPARATOR
Intervention: Generalized immunosuppressive therapy (control group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 55
Study: 9124468

Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg 30 min before and 0.75 mg 120 min after light exposure)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8166887

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg (n = 61)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (n = 64)
Number of subjects: 125
Study: 3535392

Group type: EXPERIMENTAL
Intervention: Evening primrose oil rich in gammalinolenic acid (GLA, 18:3 n‐6) (n = 13)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Marine oil concentrate containing n‐3 fatty acids (n = 14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Olive oil as placebo
Number of subjects: 27
Study: 29878825

Group type: EXPERIMENTAL
Intervention: Telephone-delivered intervention (12-month follow-up support)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 249
Study: 27825059

Group type: EXPERIMENTAL
Intervention: Islet cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive medical treatment
Number of subjects: 0
Study: 25211359

Group type: EXPERIMENTAL
Intervention: Riboflavin solution with 20% dextran
Number of subjects: 27

Group type: COMPARATOR
Intervention: Dextran-free riboflavin solution
Number of subjects: 27
Study: 22687313

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (antibiotic therapy only)
Number of subjects: 25
Study: 19878147

Group type: EXPERIMENTAL
Intervention: CR = 25% caloric restriction
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CR + EX = 12.5% CR + 12.5% increase in energy expenditure by structured exercise
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: LCD = low calorie diet until 15% weight reduction followed by weight maintenance
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control = 100% of energy requirements
Number of subjects: 43
Study: 17533467

Group type: EXPERIMENTAL
Intervention: Cooled-tip catheter (n=26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 8 mm-tip catheter (n=26)
Number of subjects: 52
Study: 16243989

Group type: EXPERIMENTAL
Intervention: ODT ondansetron 8 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: IV ondansetron 4 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 12108616

Group type: EXPERIMENTAL
Intervention: Intravenous porcine secretin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10665675

Group type: EXPERIMENTAL
Intervention: Robot-aided therapy during acute rehabilitation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard acute rehabilitation treatment
Number of subjects: 20
Study: 7885806

Group type: EXPERIMENTAL
Intervention: Moving visual stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stationary surround
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-vision condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surround velocities between 4 and 40 degrees/sec
Number of subjects: 0
Study: 2533023

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg/die for 14 days)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Piroxicam beta-cyclodextrin (20 mg/die for 14 days)
Number of subjects: 63
Study: 30083399

Group type: EXPERIMENTAL
Intervention: Flutter(R) device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active Cycle of Breathing Techniques (ACBT)
Number of subjects: 40
Study: 28749822

Group type: EXPERIMENTAL
Intervention: HIV(+) with cHB
Number of subjects: 2463

Group type: COMPARATOR
Intervention: HIV(+) without cHB
Number of subjects: 2463

Group type: EXPERIMENTAL
Intervention: HIV(+)
Number of subjects: 2463

Group type: COMPARATOR
Intervention: HIV(‐)
Number of subjects: 2463
Study: 24413071

Group type: EXPERIMENTAL
Intervention: Two-day physical plus cognitive exercise group (two 60-min sessions a week of aerobic and cognitive exercises)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Two-day exercise group (two 60-min sessions a week of aerobic exercises)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 138
Study: 24294744

Group type: EXPERIMENTAL
Intervention: Local probiotics vaginal medicine (10 applications) containing Lactobacillus acidophilus and Lactobacillus rhamnosus
Number of subjects: 381

Group type: COMPARATOR
Intervention: Clindamycin (600 mg BID for 5 days) + 2 vaginal ovules of Metronidazole (1000 mg each, every other day)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg BID for 5 days) + 2 vaginal ovules of Metronidazole (1000 mg each, every other day) + local probiotics (starting day 5)
Number of subjects: 381
Study: 21569374

Group type: EXPERIMENTAL
Intervention: Temporary ovarian suspension (elevating both ovaries to the anterior abdominal wall using a Prolene suture) post-operatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (a new transabdominal suture reinserted to act as a placebo)
Number of subjects: 0
Study: 19450759

Group type: EXPERIMENTAL
Intervention: Early cyclosporine-A (CsA) on day -7
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional cyclosporine-A (CsA) on day -1
Number of subjects: 152
Study: 17030174

Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a plus ribavirin
Number of subjects: 516

Group type: COMPARATOR
Intervention: pegylated interferon alfa alone
Number of subjects: 516
Study: 14628238

Group type: EXPERIMENTAL
Intervention: Tourniquet released before wound closure
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tourniquet released after wound closure
Number of subjects: 70
Study: 11134099

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 50 mg/day
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 100 mg/day
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 50 mg to 75 mg/day
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 100 mg to 75 mg/day
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (both doses)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel
Number of subjects: 227

Group type: COMPARATOR
Intervention: Transdermal testosterone patch (2 patches delivering 5 mg T/day)
Number of subjects: 227
Study: 9307537

Group type: EXPERIMENTAL
Intervention: Single dose of prostaglandin E2 (2 mg)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Two doses of prostaglandin E2 (2 mg each, second dose after six hours if needed)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Two doses of prostaglandin E2 (2 mg each)
Number of subjects: 955
Study: 8349432

Group type: EXPERIMENTAL
Intervention: Oral menogaril (85 mg/m2 to 625 mg/m2 every 4 weeks)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Alternating oral and IV menogaril (250 mg/m2 IV; 250-500 mg/m2 oral)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oral menogaril
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IV menogaril
Number of subjects: 47
Study: 3525736

Group type: EXPERIMENTAL
Intervention: Erythromycin (one-week course)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 29439844

Group type: EXPERIMENTAL
Intervention: Quit immediately group (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cut down to quit group (n=50)
Number of subjects: 100
Study: 26403265

Group type: EXPERIMENTAL
Intervention: Activated protein C (APC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24326361

Group type: EXPERIMENTAL
Intervention: NCB®‐DF (polyaxial locking plates)
Number of subjects: 27

Group type: COMPARATOR
Intervention: LISS® (monoaxial locking plates)
Number of subjects: 27
Study: 22471138

Group type: EXPERIMENTAL
Intervention: Warming‐promotion needling technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine needling technique
Number of subjects: 30
Study: 21254734

Group type: EXPERIMENTAL
Intervention: TURP (Transurethral Resection of the Prostate)
Number of subjects: 0
Study: 19068454

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day, 4 weeks 'on' and 2 weeks 'off')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study: 16789966

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15272999

Group type: EXPERIMENTAL
Intervention: Prevention pride orientation in HRS individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived rejection in HRS individuals high in prevention pride
Number of subjects: 0
Study: 10937788

Group type: EXPERIMENTAL
Intervention: Computer-administered SCL-90-R
Number of subjects: 282

Group type: COMPARATOR
Intervention: Paper-and-pencil SCL-90-R
Number of subjects: 282
Study: 9350186

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical regimen modification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutropenic episodes with clinically defined infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutropenic episodes without a focus
Number of subjects: 0
Study: 8146033

Group type: EXPERIMENTAL
Intervention: 75 mg maprotiline
Number of subjects: 20

Group type: COMPARATOR
Intervention: 500 mg aminophylline
Number of subjects: 20
Study: 2873974

Group type: EXPERIMENTAL
Intervention: Lidamidine (10 mg per os)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31837126

Group type: EXPERIMENTAL
Intervention: Physiotherapy-led exercise
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Enhanced exercise-based care
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Usual exercise-based care
Number of subjects: 1083
Study: 29986611

Group type: EXPERIMENTAL
Intervention: 20 units of elcatonin (EL group)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 869
Study: 28249107

Group type: EXPERIMENTAL
Intervention: Modified dissonance-based eating disorder program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 47
Study: 25581207

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 329
Study: 22488783

Group type: EXPERIMENTAL
Intervention: Early PCI (within 24 hours of presentation)
Number of subjects: 13762

Group type: COMPARATOR
Intervention: Delayed PCI (more than 24 hours after presentation)
Number of subjects: 13762
Study: 21332653

Group type: EXPERIMENTAL
Intervention: 100‐min infusion of gemcitabine
Number of subjects: 32

Group type: COMPARATOR
Intervention: 30‐min infusion of gemcitabine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prolonged infusion after week 1
Number of subjects: 32
Study: 20178214

Group type: EXPERIMENTAL
Intervention: Storage in saline water at 37 degrees C
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Storage inside roots of extracted human teeth immersed in saline water at 37 degrees C
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Storage in mineral oil at 37 degrees C
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Storage in dry conditions at 37 degrees C
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DT Light Post, GC Post, FRC Postect Plus
Number of subjects: 36
Study: 16915025

Group type: EXPERIMENTAL
Intervention: Accumulated physical activity (4 x 10‐min walks at 50% of VO2peak)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous physical activity (40‐min walk at 50% of VO2peak)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 21
Study: 15060511

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg orally once daily for 4 days
Number of subjects: 10
Study: 11755894

Group type: EXPERIMENTAL
Intervention: ADL 8‐2698 (6.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADL 8‐2698 (0.5 to 3.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADL 8‐2698 (> or = 3.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADL 8‐2698 (lower doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADL 8‐2698
Number of subjects: 0